GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Haemonetics Corp (NYSE:HAE) » Definitions » Shiller PE Ratio

Haemonetics (Haemonetics) Shiller PE Ratio

: 86.68 (As of Today)
View and export this data going back to 1991. Start your Free Trial

As of today (2024-04-16), Haemonetics's current share price is $84.08. Haemonetics's E10 for the quarter that ended in Dec. 2023 was $0.97. Haemonetics's Shiller PE Ratio for today is 86.68.

The historical rank and industry rank for Haemonetics's Shiller PE Ratio or its related term are showing as below:

HAE' s Shiller PE Ratio Range Over the Past 10 Years
Min: 27.14   Med: 87.39   Max: 223.42
Current: 86.68

During the past years, Haemonetics's highest Shiller PE Ratio was 223.42. The lowest was 27.14. And the median was 87.39.

HAE's Shiller PE Ratio is ranked worse than
90.25% of 277 companies
in the Medical Devices & Instruments industry
Industry Median: 27.33 vs HAE: 86.68

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Haemonetics's adjusted earnings per share data for the three months ended in Dec. 2023 was $0.610. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.97 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Haemonetics Shiller PE Ratio Historical Data

The historical data trend for Haemonetics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haemonetics Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Shiller PE Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 130.10 143.02 161.98 95.09 100.20

Haemonetics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 99.99 100.20 91.12 94.44 88.57

Competitive Comparison

For the Medical Instruments & Supplies subindustry, Haemonetics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Haemonetics Shiller PE Ratio Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Haemonetics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Haemonetics's Shiller PE Ratio falls into.



Haemonetics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Haemonetics's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=84.08/0.97
=86.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Haemonetics's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Haemonetics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.61/129.4194*129.4194
=0.610

Current CPI (Dec. 2023) = 129.4194.

Haemonetics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 0.190 99.695 0.247
201406 -0.070 100.560 -0.090
201409 0.140 100.428 0.180
201412 0.310 99.070 0.405
201503 -0.060 99.621 -0.078
201506 -0.010 100.684 -0.013
201509 0.250 100.392 0.322
201512 -1.170 99.792 -1.517
201603 -0.173 100.470 -0.223
201606 -0.200 101.688 -0.255
201609 0.380 101.861 0.483
201612 0.300 101.863 0.381
201703 -0.984 102.862 -1.238
201706 0.380 103.349 0.476
201709 0.380 104.136 0.472
201712 -0.120 104.011 -0.149
201803 0.220 105.290 0.270
201806 -0.050 106.317 -0.061
201809 0.350 106.507 0.425
201812 0.350 105.998 0.427
201903 0.400 107.251 0.483
201906 -0.170 108.070 -0.204
201909 0.720 108.329 0.860
201912 0.580 108.420 0.692
202003 0.350 108.902 0.416
202006 0.210 108.767 0.250
202009 0.940 109.815 1.108
202012 0.620 109.897 0.730
202103 -0.220 111.754 -0.255
202106 -0.090 114.631 -0.102
202109 0.290 115.734 0.324
202112 0.450 117.630 0.495
202203 0.190 121.301 0.203
202206 0.380 125.017 0.393
202209 0.640 125.227 0.661
202212 0.640 125.222 0.661
202303 0.570 127.348 0.579
202306 0.800 128.729 0.804
202309 0.480 129.860 0.478
202312 0.610 129.419 0.610

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Haemonetics  (NYSE:HAE) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Haemonetics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Haemonetics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Haemonetics (Haemonetics) Business Description

Traded in Other Exchanges
Address
125 Summer Street, Boston, MA, USA, 02110
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Executives
Stewart W Strong officer: President, Global Hospital C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Anila Lingamneni officer: EVP, Chief Technology Officer HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Charles J Dockendorff director COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Diane M Bryant director 2200 MISSION COLLEGE BLVD, SANTA CLARA CA 95054
Josep Llorens officer: EVP, Global Manufacturing HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Michelle L Basil officer: EVP and General Counsel HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Farris Maryanne Maunsell officer: VP, Chief Accounting Officer C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Roy Galvin officer: President, Global Plasma & BC C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Laurie A. Miller officer: SVP, Human Resources C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Mark W Kroll director PO BOX 23, CRYSTAL BAY MN 55323
Dan Goldstein officer: VP, Corporate Controller HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Christopher Simon, director, officer: President & CEO HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
James Darecca officer: EVP, Chief Financial Officer C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Burke William P. Mr. officer: EVP, Chief Financial Officer HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Lloyd Emerson Johnson director 16737 NEW PROVIDENCE LANE, CHARLOTTE NC 28277